Titre : Catéchine

Catéchine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Multicenter Studies as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Catéchine : Questions médicales les plus fréquentes", "headline": "Catéchine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Catéchine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-14", "dateModified": "2025-05-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Catéchine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Flavonoïdes", "url": "https://questionsmedicales.fr/mesh/D005419", "about": { "@type": "MedicalCondition", "name": "Flavonoïdes", "code": { "@type": "MedicalCode", "code": "D005419", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.150.266.450" } } }, "about": { "@type": "MedicalCondition", "name": "Catéchine", "alternateName": "Catechin", "code": { "@type": "MedicalCode", "code": "D002392", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jae Sik Yu", "url": "https://questionsmedicales.fr/author/Jae%20Sik%20Yu", "affiliation": { "@type": "Organization", "name": "School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea." } }, { "@type": "Person", "name": "Ki Hyun Kim", "url": "https://questionsmedicales.fr/author/Ki%20Hyun%20Kim", "affiliation": { "@type": "Organization", "name": "School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea." } }, { "@type": "Person", "name": "Masaharu Shin-Ya", "url": "https://questionsmedicales.fr/author/Masaharu%20Shin-Ya", "affiliation": { "@type": "Organization", "name": "Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan." } }, { "@type": "Person", "name": "Eriko Ohgitani", "url": "https://questionsmedicales.fr/author/Eriko%20Ohgitani", "affiliation": { "@type": "Organization", "name": "Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan." } }, { "@type": "Person", "name": "Masaya Kawamoto", "url": "https://questionsmedicales.fr/author/Masaya%20Kawamoto", "affiliation": { "@type": "Organization", "name": "Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Proximal hyperdense middle cerebral artery sign is associated with increased risk of asymptomatic hemorrhagic transformation after endovascular thrombectomy: a multicenter retrospective study.", "datePublished": "2022-11-29", "url": "https://questionsmedicales.fr/article/36446912", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00415-022-11500-5" } }, { "@type": "ScholarlyArticle", "name": "First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).", "datePublished": "2022-11-28", "url": "https://questionsmedicales.fr/article/36441560", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1161/CIRCEP.122.010915" } }, { "@type": "ScholarlyArticle", "name": "Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).", "datePublished": "2022-11-24", "url": "https://questionsmedicales.fr/article/36470801", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejso.2022.11.099" } }, { "@type": "ScholarlyArticle", "name": "Hospitalization and Mortality by Vaccination Status among COVID-19 Patients Aged ≥ 25 Years in Bangladesh: Results from a Multicenter Cross-Sectional Study.", "datePublished": "2022-11-23", "url": "https://questionsmedicales.fr/article/36560397", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/vaccines10121987" } }, { "@type": "ScholarlyArticle", "name": "Evaluation of the physical and emotional effects of the COVID-19 pandemic on patients with fibromyalgia and chronic low back pain: A multicenter cross-sectional controlled study.", "datePublished": "2022-11-22", "url": "https://questionsmedicales.fr/article/36589358", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5606/tftrd.2022.10053" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzopyranes", "item": "https://questionsmedicales.fr/mesh/D001578" }, { "@type": "ListItem", "position": 6, "name": "4H-1-Benzopyran-4-ones", "item": "https://questionsmedicales.fr/mesh/D002867" }, { "@type": "ListItem", "position": 7, "name": "Flavonoïdes", "item": "https://questionsmedicales.fr/mesh/D005419" }, { "@type": "ListItem", "position": 8, "name": "Catéchine", "item": "https://questionsmedicales.fr/mesh/D002392" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Catéchine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Catéchine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Catéchine", "description": "Comment mesurer les niveaux de catéchines dans le corps ?\nQuels tests sont utilisés pour évaluer l'impact des catéchines ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Multicenter+Studies+as+Topic&page=999#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Catéchine", "description": "Quels sont les effets secondaires des catéchines ?\nLes catéchines provoquent-elles des allergies ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Multicenter+Studies+as+Topic&page=999#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Catéchine", "description": "Les catéchines aident-elles à prévenir les maladies cardiaques ?\nComment intégrer les catéchines dans l'alimentation ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Multicenter+Studies+as+Topic&page=999#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Catéchine", "description": "Les catéchines peuvent-elles traiter des maladies ?\nComment les catéchines aident-elles à la perte de poids ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Multicenter+Studies+as+Topic&page=999#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Catéchine", "description": "Les catéchines peuvent-elles interagir avec des médicaments ?\nQuels risques sont associés à une consommation excessive de catéchines ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Multicenter+Studies+as+Topic&page=999#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Catéchine", "description": "Qui devrait éviter les catéchines ?\nLes femmes enceintes peuvent-elles consommer des catéchines ?", "url": "https://questionsmedicales.fr/mesh/D002392?mesh_terms=Multicenter+Studies+as+Topic&page=999#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer les niveaux de catéchines dans le corps ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de catéchines peuvent être mesurés par des analyses sanguines ou urinaires." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'impact des catéchines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests cliniques et des études d'observation sont utilisés pour évaluer leur impact." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des catéchines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des maux d'estomac, des nausées ou des maux de tête." } }, { "@type": "Question", "name": "Les catéchines provoquent-elles des allergies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les allergies aux catéchines sont rares, mais peuvent survenir chez certaines personnes." } }, { "@type": "Question", "name": "Les catéchines aident-elles à prévenir les maladies cardiaques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent réduire le risque de maladies cardiaques en améliorant la santé vasculaire." } }, { "@type": "Question", "name": "Comment intégrer les catéchines dans l'alimentation ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Consommer du thé vert, des fruits et des légumes riches en catéchines est recommandé." } }, { "@type": "Question", "name": "Les catéchines peuvent-elles traiter des maladies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont étudiées pour leur potentiel dans le traitement de maladies comme le cancer." } }, { "@type": "Question", "name": "Comment les catéchines aident-elles à la perte de poids ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent augmenter le métabolisme et favoriser la combustion des graisses." } }, { "@type": "Question", "name": "Les catéchines peuvent-elles interagir avec des médicaments ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent interagir avec certains médicaments, notamment les anticoagulants." } }, { "@type": "Question", "name": "Quels risques sont associés à une consommation excessive de catéchines ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une consommation excessive peut entraîner des problèmes hépatiques ou des troubles digestifs." } }, { "@type": "Question", "name": "Qui devrait éviter les catéchines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des problèmes hépatiques ou des allergies doivent être prudentes." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles consommer des catéchines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles doivent consulter un médecin avant de consommer des catéchines en grande quantité." } } ] } ] }

Sources (10000 au total)

Proximal hyperdense middle cerebral artery sign is associated with increased risk of asymptomatic hemorrhagic transformation after endovascular thrombectomy: a multicenter retrospective study.

To investigate whether hyperdense middle cerebral artery sign (HMCAS) on pretreatment no-contrast CT (NCCT) is associated with hemorrhagic transformation (HT) after endovascular thrombectomy (EVT).... Patients with acute middle cerebral artery (MCA) occlusion who received EVT in three comprehensive hospitals were retrospectively evaluated. They were divided into four groups based on the presence or... 318 patients were included, among whom 149 (46.9%) had HMCAS. Patients in the proximal positive HMCAS group had higher National Institute of Health Stroke Scale scores and lower Alberta Stroke Program... Proximal HMCAS on initial NCCT was independently associated with aHT in patients who received EVT for acute MCA occlusion. Both aHT and sHT had a detrimental effect on clinical outcome....

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).

Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridin... NODE-301, a phase 3, multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of etripamil nasal spray administered, unsupervised in patients with symptomatic sustained PS... NODE-301 accrued 156 positively adjudicated PSVT events treated with etripamil (n=107) or placebo (n=49). The hazard ratio for the primary endpoint, time-to-conversion to sinus rhythm during the 5-hou... Although the primary 5-hour efficacy endpoint was not met, analyses at earlier time points indicated an etripamil treatment effect in terminating PSVT. Etripamil self-administration during PSVT was sa... URL: https://www.... gov; Unique identifier: NCT03464019....

Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).

We evaluated the impact of omitting axillary lymph node dissection (ALND) on oncological outcomes in breast cancer patients with residual nodal disease after neoadjuvant chemotherapy (NAC).... The medical records of patients who underwent NAC followed by surgical resection and had residual nodal disease were retrospectively reviewed. In total, 1273 patients from 12 institutions were include... The median follow-up was 75.3 months (range, 2.5-182.7). Axillary recurrence rates were 4.8% in the ALND group (n = 53) and 4.7% in the SLNBx group (n = 8). Before PSM, univariate analysis indicated t... SLNBx alone did not compromise oncological outcomes in patients with residual nodal disease after NAC. The omission of ALND might be a possible option for axillary management in patients treated with ...

Evaluation of the physical and emotional effects of the COVID-19 pandemic on patients with fibromyalgia and chronic low back pain: A multicenter cross-sectional controlled study.

This study aimed to investigate the physical and emotional effects of the coronavirus disease 2019 pandemic in patients with fibromyalgia syndrome (FMS) and chronic low back pain (CLBP) patients.... The cross-sectional controlled study was performed with 1,360 participants (332 males, 1,028 females; mean age: 42.3±12.5 years; range, 18 to 65 years) between September 2020 and February 2021. The pa... Patients with FMS had worsened general health status and pain levels during the pandemic compared to the other groups (p<0.01). The FMS group showed significantly higher PSS scores than those in other... The general health status, pain, and stress levels of the patients with FMS and CLBP tended to worsen during the pandemic. This high-stress level appeared to affect disease activity in patients with F...

Prevalence and Risk Factor Analysis of Post-Intensive Care Syndrome in Patients with COVID-19 Requiring Mechanical Ventilation: A Multicenter Prospective Observational Study.

Post-intensive care syndrome (PICS) is an emerging problem in critically ill patients and the prevalence and risk factors are unclear in patients with severe coronavirus disease 2019 (COVID-19). This ... Questionnaires were administered twice in surviving patients with COVID-19 who had required mechanical ventilation, concerning Barthel Index, Short-Memory Questionnaire, and Hospital Anxiety and Depre... The first and second PICS surveys were obtained at 5.5 and 13.5 months (mean) after ICU discharge, with 251 and 209 patients completing the questionnaires and with a prevalence of PICS of 58.6% and 60... Approximately 60% of the ventilated patients with COVID-19 experienced persistent PICS, especially delirium, and required longer mechanical ventilation....

Predictors of transfer from a remote trauma facility to an urban level I trauma center for blunt splenic injuries: a retrospective observational multicenter study.

The decision-making for admission versus emergent transfer of patients with blunt splenic injuries presenting to remote trauma centers with limited resources remains a challenge. Although splenectomy ... A retrospective observational study was performed to examine the management of splenic injuries at a mountainous and remote Level III trauma center. Trauma patients ≥ 18 years who had a blunt splenic ... Of the 73 patients included with a blunt splenic injury, 48% were admitted and 52% were transferred to a Level I facility. Most patients were male (n = 58), were a median age of 26 (21-42) years old, ... Our data suggest that most patients transferred from a remote facility had a splenic injury grade ≥ 3, with concomitant injuries but were hemodynamically stable and were successfully managed non-opera...

RESCUE BT 2, a multicenter, randomized, double-blind, double-dummy trial of intravenous tirofiban in acute ischemic stroke: Study rationale and design.

Tirofiban is a glycoprotein IIb/IIIa receptor inhibitor that has been shown to be effective in the treatment of acute coronary syndromes. However, it remains unknown whether it improves outcomes in pa... This trial investigates the efficacy and safety of tirofiban compared with aspirin for acute ischemic stroke within 24 h after symptom onset.... The Efficacy and Safety of Tirofiban Compared with Aspirin in the Treatment of Acute Ischemic Stroke (RESCUE BT 2) Trial is an investigator-initiated, prospective, randomized, double-blind, double-dum... The primary endpoint is the proportion of patients with excellent functional outcomes defined as a modified Rankin scale score of 0 to 1 at 90 days after randomization. Lead safety endpoints include m... ChiCTR2000029502 (www.chictr.org.cn)....